Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=85 Amgen 386 for Recurrent Glioblastoma
Glioblastoma Multiforme
Primary: 6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B] — 0.243; 0 proportion of participants
Phase 2 N=39 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Malignant Glioma
Primary: Six-month Progression-free Survival (PFS6) — 14.3; 5; 14.3; 40 percentage of participants
Phase 1 N=71 Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
Astrocytoma, Grade III · Glioblastoma
Primary: Maximum Tolerated Dose (MTD) — 150; 150 mg
Phase 2 N=72 Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Neoplasms
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Daily Oral Lisavanbulin — 16; 30 mg
Phase 2 N=159 Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Glioblastoma
Primary: Overall Survival Rate at 12 Months (OS-12) as Estimated Using the Kaplan-Meier Method (Cohort A) — 60.0 percent of subjects alive
Phase 2 N=93 A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) · Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) · Cohort 3a and 3b: Chondrosarcoma
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 0; 2; 0; 1 Participants
Phase 2 N=121 Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Malignant Glioma · Glioblastoma
Primary: Radiographic Objective Response Rate (ORR) - Part 2 Cohort — 3.3 Percent of participants
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 2 N=62 Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Phase 2 N=177 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
High Grade Glioma · Astrocytoma, Grade III · Glioblastoma
Primary: Phase 1: Maximum Tolerated Dose (MTD) of BMX-001 Administered in Combination With Standard RT and TMZ in Newly Diagnosed HGG Patients — NA mg/Participant
Phase 2 N=22 Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Number of Participants Who Experienced Treatment-related Dose Limiting Toxicities (DLT) — 0; 0 Participants
Phase 2 N=30 Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme of Brain
Primary: Safety and Tolerability — 19; 2; 2; 2 participants
Phase 2 N=4 Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BAL101553 — 70 mg/m²
Phase 2 N=33 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Gliomas
Primary: Overall Response Rate — 9 percent
Phase 2 N=26 A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Phase 2 N=35 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Glioblastoma · Glioblastoma Multiforme · Gliosarcoma
Primary: Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With…
Phase 2 N=30 Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Glioblastoma, Adult
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 2 Participants
Phase 2 N=66 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Phase 2 N=38 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Giant Cell Glioblastoma · Adult Gliosarcoma
Primary: Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma — 0; 0; NA; 0 DLTs
Phase 1 N=24 IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Phase 2 N=151 BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Glioma
Primary: Number of Participants With DLT- Phase I — 2; 0; 4 participants
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Phase 2 N=180 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
N/A N=1 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
Phase 2 N=265 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Glioblastoma
Primary: Overall Survival (OS) Time — 16.3; 14.5; 13.4 Months — p=0.0328
Phase 2 N=13 Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Brain Tumor · Glioblastoma · Anaplastic Glioma
Primary: Maximum Tolerated Dose of Everolimus for Participants With Recurrent Malignant Gliomas — 5 mg
Phase 2 N=65 Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Glioblastoma
Primary: Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1] — 6; 1; 7; 1 Participants